Brown Erin G, Engwall-Gill Abigail J, Aldrink Jennifer H, Ehrlich Peter F, Fawcett Andrea, Coakley Brian A, Rothstein David H, Rich Barrie S, Glick Richard D, Baertschiger Reto M, Roach Jonathan P, Lautz Timothy B
Division of Pediatric Surgery, Department of Surgery, University of California Davis Children's Hospital, Sacramento, CA, USA.
Department of Surgery, Michigan State University, Sparrow Hospital, Lansing, MI, USA.
J Pediatr Surg. 2023 Nov;58(11):2128-2134. doi: 10.1016/j.jpedsurg.2023.07.011. Epub 2023 Aug 1.
Nephrogenic rests (NR) may represent precursor lesions for Wilms tumor (WT), but their clinical course is not fully understood and no guidelines for treatment exist. This study sought to evaluate the outcomes of pediatric patients with NRs related to traditional chemotherapy and surgery.
A PRISMA-P-compliant literature search was conducted in MEDLINE, Embase, CINAHL, Web of Science, COCHRANE, and SCOPUS from inception to June 2021. Clinical questions regarding the treatment of NRs, including chemotherapy and surgery, were developed in the population, intervention, comparison, and outcome format.
Twenty-five studies including 1445 patients met inclusion criteria for evaluating chemotherapy compared to observation for NRs. Eighteen studies including 1392 patients met inclusion criteria for evaluating the role of surgery for NRs. Patients with isolated NRs who underwent observation progressed to WT 33% of the time; chemotherapy reduced the rate of WT to 3.9%. Observation of multiple NRs and diffuse hyperplastic perilobar nephroblastomatosis (DHPLN) led to progression to WT 50% and 100% of the time, respectively. Chemotherapy reduced the rate of WT to 34% for multiple NRs and 46% for DHPLN. Surgery for isolated NRs reduced the risk of WT development from 23.7% in patients with incomplete excision to 3.3% with complete excision; however, 96% of patients with incompletely excised NRs had bilateral disease.
Observation with close surveillance for isolated NRs is safe. Treatment with chemotherapy is recommended for patients with multiple NRs and DHPLN. Surgical management of NRs should focus on renal function preservation.
Treatment study, Level III.
肾源性残留(NR)可能是肾母细胞瘤(WT)的前驱病变,但其临床病程尚未完全明确,且尚无治疗指南。本研究旨在评估接受传统化疗和手术的小儿NR患者的治疗结果。
从创刊至2021年6月,在MEDLINE、Embase、CINAHL、Web of Science、COCHRANE和SCOPUS数据库中进行了符合PRISMA-P标准的文献检索。以人群、干预措施、对照和结局的形式提出了关于NR治疗的临床问题,包括化疗和手术。
25项研究(共1445例患者)符合评估NR化疗与观察对比的纳入标准。18项研究(共1392例患者)符合评估手术对NR作用的纳入标准。接受观察的孤立性NR患者有33%进展为WT;化疗将WT发生率降至3.9%。观察多发性NR和弥漫性增生性叶旁肾母细胞瘤(DHPLN)分别有50%和100%的患者进展为WT。化疗将多发性NR患者的WT发生率降至34%,将DHPLN患者的WT发生率降至46%。孤立性NR手术将WT发生风险从不完全切除患者的23.7%降至完全切除患者的3.3%;然而,96%不完全切除NR的患者患有双侧疾病。
对孤立性NR进行密切监测下的观察是安全的。推荐对多发性NR和DHPLN患者进行化疗。NR的手术管理应注重肾功能的保留。
治疗研究,III级。